德克斯普拉米佩克索尔在异性喘 (EXHALE) 的安全性和有效性:一项随机对照试验
Salman Siddiqui1, Sally E Wenzel2, Michael E Bozik3
1National Heart and Lung Institute, Imperial College, London, United Kingdom.
The Journal of allergy and clinical immunology
|June 5, 2023
概括
德克斯普拉米佩克索尔有效降低了中度至重度喘的成年人血液中异氨基的水平. 这种口服治疗耐受性良好,表明未来喘治疗的潜力,等待更大的临床试验.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 呼吸系统医学 呼吸系统医学
- 临床试验 临床试验
背景情况:
- 对于治疗喘的新型口服疗法有显著的需求.
- 德克斯普拉米佩克索尔是一种口服药物,向乙氨基酸,以前没有在喘患者中进行过研究.
研究的目的:
- 评估德克斯普拉米佩克索尔在降低血液和呼吸道异敏症方面的安全性和有效性.
- 为了评估德克斯普拉米佩克索尔对酸性喘的影响.
主要方法:
- 一项随机,双盲,安慰剂对照试验在患有中度至重度喘的成年人中进行.
- 绝对乙酸细胞计数 (AEC) >=300/μL的参与者接受了德克斯普拉米醇 (37.5,75,或150毫克每天两次) 或安慰剂.
- 主要终点:AEC在12周的相对变化;次要终点:FEV1的变化;探索性终点:鼻氨基酸过氧化酶.
主要成果:
- 在每天两次服用75毫克和150毫克组,12周后,德克斯普拉米佩克索尔显著降低了安慰剂校正的AEC (分别降低了77%和66%).
- 在每天两次服用75毫克和150毫克的组中观察到鼻氨基酸过氧化酶的减少.
- 发现了有利的安全性概况,从第4周开始观察到FEV1的非显著增加.
结论:
- 德克斯普拉米佩克索尔表现出强烈的低氨基细胞降低能力,并且在本研究群体中耐受良好.
- 需要进一步的大规模临床试验来证实德克斯普拉米佩克索尔在喘治疗中的临床疗效.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
358
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
358
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:19Antiasthma Drugs: Leukotriene Modifiers
375
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
375
01:24Antiasthma Drugs: Methylxanthines
281
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
281
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
318
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
318
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
350
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
350